Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN SODIUM versus LOVENOX PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN SODIUM versus LOVENOX PRESERVATIVE FREE.
ENOXAPARIN SODIUM vs LOVENOX (PRESERVATIVE FREE)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
None Documented
None Documented
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with CrCl <30 mL/min).
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin